NeuroOne Medical Technologies Corporation reported significant financial developments in its recent 10-K filing for the fiscal year ending September 30, 2025. The company generated product revenue of approximately $9.1 million, a substantial increase from $3.5 million in the previous fiscal year, marking a growth of 163%. This increase was primarily driven by sales of the OneRF Ablation System, which was introduced under a distribution agreement with Zimmer, Inc. The gross profit for the year was reported at $5.1 million, reflecting a gross profit margin of 56.5%, up from 31.3% in the prior year. The company’s net loss narrowed to $3.6 million from $12.3 million, indicating improved operational efficiency.
In terms of strategic developments, NeuroOne received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System in August 2025, which is expected to enhance its product offerings in the pain management sector. The company also amended its distribution agreement with Zimmer, granting exclusive rights to distribute the OneRF Ablation System for an upfront payment of $3 million, with potential additional payments based on sales milestones. This partnership is crucial for NeuroOne as it relies on Zimmer to drive commercialization efforts for its products.
Operationally, NeuroOne reported a total of 50 million shares outstanding as of September 30, 2025, an increase from 30.8 million shares the previous year. The company’s employee headcount remained stable at 18 full-time employees, with eight engaged in research and development. The company’s cash and cash equivalents stood at approximately $6.6 million, which management indicated may not be sufficient to fund operations for the next twelve months without additional capital raising efforts. The company has expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for further financing.
Looking ahead, NeuroOne aims to expand its market presence and product adoption, particularly in the U.S. and select international markets. The company plans to leverage its existing technologies and partnerships to enhance its product portfolio, including ongoing development of drug delivery systems that utilize its sEEG electrode technology. However, the company acknowledges that achieving profitability will depend on successful commercialization and market acceptance of its products, as well as securing adequate reimbursement coverage from third-party payors.
In summary, NeuroOne Medical Technologies Corporation is navigating a critical phase of growth, marked by increased revenues and strategic partnerships, while also facing challenges related to funding and market acceptance of its innovative medical technologies.
About NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies develops advanced thin film electrode technology for diagnosing and treating neurological disorders such as epilepsy, Parkinson’s disease, dystonia, and chronic pain. Its core products include cortical and sEEG electrodes, ablation systems, and stimulation devices, primarily targeting the U.S. market. The company focuses on minimally invasive solutions, integrated diagnostic and therapeutic tools, and leveraging scalable manufacturing to improve clinical outcomes and reduce procedural risks.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.